Polyoxidonium - instructions for use, doses, side effects, contraindications

Active substanceAzoxime bromideAzoxime bromide

Similar drugsTo uncover

Polyoxidonium®

lyophilizate locally w / m in / in

NPO PETROVAKS PHARM, LLC Russia

Polyoxidonium®

suppositories rect. the vagina.

NPO PETROVAKS PHARM, LLC Russia

Polyoxidonium®

pills inwards

NPO PETROVAKS PHARM, LLC Russia

Polyoxidonium®

suppositories rect. the vagina.

NPO PETROVAKS PHARM, LLC Russia

Dosage form: & nbspsuppositories vaginal and rectal based on solid fat

Composition:

Active substance: Polyoxidonium® (Azoxime bromide) 6 mg or 12 mg

Excipients: mannitol, povidone, betacarotene

The basis: hard fat

Description:Suppositories torpedo, shaped from white with a yellowish hue to light yellow color.

Pharmacotherapeutic group:Immunomodulating agent

ATX: & nbsp

L.03.A.X Other immunostimulants

Pharmacodynamics:

Polyoxidonium® has an immunomodulatory effect, increases the body's resistance to local and generalized infections. The basis of the mechanism of immunomodulatory action of Polyoxidonium ® is a direct effect on phagocytic cells and natural killers, as well as stimulation of antibody formation.

Polyoxidonium® restores immunity to secondary immunodeficiency states caused by various infections, injuries, burns,autoimmune diseases, malignant neoplasms, complications after surgical operations, the use of chemotherapeutic agents, cytostatics, steroid hormones.

Along with the immunomodulating effect, Polyoxidonium has a pronounced detoxification and antioxidant activity, has the ability to excrete toxins from the body, salts of heavy metals, inhibits lipid peroxidation. These properties are determined by the structure and high molecular weight nature of Polyoxidonium®. The inclusion of Polyoxidonium® in the complex therapy of cancer patients reduces the intoxication on the background of chemo- and radiotherapy, in most cases allows treatment without changing the standard therapy regimen due to the development of infectious complications and side effects (myelosuppression, vomiting, diarrhea, cystitis, colitis and others ).

The use of Polyoxidonium® on the background of secondary immunodeficiency states allows to increase the efficiency and shorten the duration of treatment, significantly reduce the use of antibiotics, bronchodilators, glucocorticosteroids, and prolong the period of remission.

The drug is well tolerated, does not have mitogenic, polyclonal activity, antigenic properties. Does not have allergic, mutagenic, embryotoxic, teratogenic and carcinogenic effects.

Pharmacokinetics:

Polyoxidonium® in suppositories with rectal administration has a high bioavailability (at least 70%), reaching a maximum concentration in the blood 1 hour after administration. The half-distribution period is about 0.5 hours, the half-elimination period is 36.2 hours. In the body it is hydrolyzed to oligomers, which are excreted mainly by the kidneys. There is no cumulative effect.

Indications:

In adults and children over 6 years of age in complex therapies for the correction of immune deficiency:

- chronic recurrent infectious-inflammatory diseases, which are not amenable to standard therapy, both in the stage of exacerbation and in the stage of remission; acute viral, bacterial and fungal infections;

- inflammatory diseases of the urogenital tract, including urethritis, cystitis, pyelonephritis, prostatitis, salpingoophoritis, endomyometritis, colpitis, cervicitis, cervicosis, bacterial vaginosis, including viral etiology; various forms of tuberculosis;

- allergic diseases complicated by recurrent bacterial, fungal and viral infection (including pollinosis, bronchial asthma, atopic dermatitis);

- Rheumatoid arthritis, long-term treated with immunosuppressants; with complicated ARI or ODS of the course of the disease;

for activation of regenerative processes (fractures, burns, trophic ulcers); for rehabilitation often and for a long time (more than 4-5 times a year) of ill persons; in the course and after chemo-and radiation therapy of tumors; to reduce nephro - and hepatotoxic effects of drugs.

In the form of monotherapy:

- for the prevention of recurrent herpetic infection;

- for seasonal prevention of exacerbations of chronic foci of infections; for the prevention of influenza and acute respiratory infections in the pre-epidemic period;

for the correction of secondary immunodeficiencies due to aging or exposure to adverse factors.

Contraindications:

Individual hypersensitivity. Pregnancy (clinical experience of use is absent).

Carefully:

Acute kidney failure.

Dosing and Administration:

Polyoxidonium® suppositories 6 mg and 12 mg are applied rectally and vaginally 1 time per day. The method and dosage regimen is determined by the doctor depending on the diagnosis, severity and severity of the process. Polyoxidonium® can be applied rectally and vaginally daily, every other day, or twice a week.

Polyoxidonium® suppositories 12 mg applies in adults rectally by 1 suppository once a day after bowel cleansing; with gynecological diseases and vaginally 1 suppository once a day (at night) is inserted into the vagina in the supine position.

Polyoxidonium® suppositories 6 mg applies: in children over 6 years of age rectally by 1 suppository 1 once a day after cleansing the intestines; in adults rectally and vaginally as a maintenance dose of 1 suppository 1 Once a day (at night) is inserted into the vagina in the lying position.

Standard Application Scheme

1 suppository 6 mg or 12 mg once a day daily for 3 days, then a day later with a course of 10-20 suppositories.

If necessary, the course of treatment is repeated after 3-4 months.

For patients who have been receiving immunosuppressive therapy for a long time, oncological patients with acquired immune system defect - HIV, exposed to radiation, sustained maintenance from 2-3 months to 1 year with Polyoxidonium ® (adults of 12 mg, children 6 years and older - 6 mg 1 -2 times per week).

Variants of recommended regimens for use in complex therapy

When chronic infectious-inflammatory diseases in the stage of exacerbation - according to the standard scheme, in the stage of remission - according to the 1 suppository through 1-2 day, general course 10-15 suppositories.

At acute, infectious processes and for activation of regenerative processes (fractures, burns, trophic ulcers) - daily for 1 suppository. The course of treatment - 10-15 suppositories;

When tuberculosis - according to the standard scheme. The course of treatment - at least 15 suppositories, then it is possible to use maintenance therapy for 2 suppositories per week for up to 2-3 months;

On the background of chemo-and radiation therapy of tumors - 1 suppository daily for 2-3 days before the start of the course of therapy. Further, the frequency of administration of suppositories, determined by the doctor, depending on the tolerability and duration of chemotherapy and radiation therapy;

For rehabilitation often (more than 4-5 times a year) and long-term ill persons and with rheumatoid arthritis - 1 suppository every other day. The course of treatment - 10 - 15 suppositories;

For the correction of secondary immunodeficiencies, including those arising from aging - 1 suppository 12 mg twice a week.Course - not less than 10 suppositories 2-3 times a year;

In the form of monotherapy:

For seasonal prevention of exacerbations of chronic foci of infections, for the prevention of recurrent herpetic infection - every other day in adults 6-12 mg, in children 6 mg each. Course - 10 suppositories;

For correction of secondary immunodeficiencies, prevention of influenza and acute respiratory disease - by the standard scheme;

When gynecological diseases rectally and vaginally - according to the standard scheme.

Side effects:

Not found.

Overdose:

Not described.

Interaction:

Polyoxidonium ® is combined with many medicines, including compatible with antibiotics, antiviral, antifungal and antihistamine drugs, glucocorticosteroids and cytostatics.

Special instructions:

Do not exceed these doses and the duration of treatment without consulting your doctor.

Form release / dosage:Suppositories vaginal and rectal based on solid fat 6 mg or 12 mg.

Packaging:

Suppositories vaginal and rectal based on solid fat of 6 mg or 12 mg of 5 pieces in a planar cell package. 2 cell packs in a cardboard box with instructions for use.

Storage conditions:

List B.In dry, sheltered from light, out of reach of children at a temperature of + 8 ° to + 15 ° C.

Shelf life:

2 years. Do not use the drug after the expiration date indicated on the packaging.

Terms of leave from pharmacies:Without recipe

Registration number:LSR-005942/09

Date of registration:21.07.2009

The owner of the registration certificate:NPO PETROVAKS PHARM, LLC NPO PETROVAKS PHARM, LLC Russia

Manufacturer: & nbsp

NPO PETROVAKS PHARM, LLC Russia

Information update date: & nbsp20.08.2015

Illustrated instructions

Instructions

Polyoxidonium® (Polyoxidonium®)